Results 161 to 170 of about 39,168 (261)

Inflammation and Diabetic Kidney Disease. [PDF]

Int J Mol Sci
Zhang RM, Caramori ML.
europepmc   +1 more source

Long‐Term Impact of Prosthesis‐Patient Mismatch After Transcatheter Aortic Valve Replacement in Patients With Small Aortic Annuli

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Prosthesis‐patient mismatch (PPM) remains common following transcatheter aortic valve replacement (TAVR) and is associated with worse clinical outcomes. PPM is of particular concern in small aortic annuli (SAA). Aims To compare the incidence, predictors, and long‐term impact of PPM in SAA TAVR.
Itamar Loewenstein, Bar Gitter, Tamar Itach, Yaron Arbel, Jeremy Ben‐Shoshan, Maayan Konigstein, Ariel Finkelstein, Amir Halkin, Shmuel Banai, Arie Steinvil   +9 more
wiley   +1 more source

Unveiling Vasculature-Associated Lymphoid Tissue (VALT) in Goats: A Novel Player in Kidney Inflammation. [PDF]

Vet Med Sci
Masum MA, Biswas S, Akter R.
europepmc   +1 more source

Collagen Fibrils within the Renal Glomerulus [PDF]

The Journal of Cell Biology, 1960
openaire   +2 more sources

Cardiovascular‐Kidney‐Metabolic Syndrome in People With HIV: An Emerging Frontier for Clinical Pharmacology

Clinical Pharmacology &Therapeutics, EarlyView.
As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular‐Kidney‐Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic (PK) alterations, ART‐associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby
Aaron S. Devanathan, Thomas D. Nolin
wiley   +1 more source

Making a portal for podocyte - parietal cell communication in glomerular injury. [PDF]

Am J Physiol Renal Physiol
Bruggeman LA.
europepmc   +1 more source

More Than a Question of Correlation: Characterization of the Evidentiary Basis for Biomarker Surrogates Used in European Marketing Authorizations

Clinical Pharmacology &Therapeutics, EarlyView.
Traditionally, clinical outcomes measuring how a patient feels, functions, or survives are preferred endpoints in clinical trials; however, some may take a long time to manifest in slowly developing diseases. Biomarkers, if properly validated, can serve as surrogate endpoints, acting as substitutes for clinical outcomes.
Renske Johanna Grupstra, Viktoriia Starokozhko, Elisabeth Bakker, Anna Maria Gerdina Pasmooij, Peter Gerardus Maria Mol   +4 more
wiley   +1 more source

Revisiting Vincristine for FSGS: Proof-of-Mechanism Arrives, but Whom Should We Treat? [PDF]

Kidney Int Rep
Guo W, Luo J, Li Z, Li X, Zhang Y, Yang J.   +5 more
europepmc   +1 more source

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID‐19 and Severe Renal Impairment

Clinical Pharmacology &Therapeutics, EarlyView.
Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment.
Jacqueline Gerhart, Candace R. Bramson, Michelle Goulding, Haihong Shi, Olayide Oladoyinbo, Phylinda L. S. Chan, Sunring Chime, Jennifer Hammond   +7 more
wiley   +1 more source

Glomerular cell atlas of multi-disease model revealed the characteristic changes of glomerular cell subtypes in diseases. [PDF]

Front Immunol
Huang Y, Li S, Li S, Duan S, Huang L, Wang J, Ma L, Liu C, Chen Q.   +8 more
europepmc   +1 more source